This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Market And Product Forecasts: Melanoma - Yervoy Will Continue To Dominate As New Approvals Struggle To Compete

NEW YORK, Nov. 14, 2012 /PRNewswire/ -- announces that a new market research report is available in its catalogue: Market and Product Forecasts: Melanoma – Yervoy will continue to dominate as new approvals struggle to compete–-Yervoy-will-continue-to-dominate-as-new-approvals-struggle-to-compete.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

The melanoma market has seen an increase in developer attention following significant breakthroughs in treatment. New approvals have raised the bar to enter the market, but with drug resistance and toxicity still major problems, there are opportunities for developers to move into this market. The entry of pipeline drugs into the market will significantly increase the value of branded sales. Analysis of melanoma drugs in the US and five major EU markets. Patient-based sales forecast for drugs in the branded melanoma market from 2012 to 2021. In-depth analysis of the factors influencing the melanoma market in individual countries. Molecule dynamics and assessment of the key melanoma drugs in the US and five major EU markets. The branded melanoma market in the US and five major EU markets ( France, Germany, Italy, Spain, and the UK) will experience significant growth over the forecast period. Sales revenue will increase from $1.1bn in 2012 to just under $2.4bn by 2021, demonstrating a compound annual growth rate (CAGR) of 9.24%. Datamonitor estimates that in 2012 the US melanoma market will be worth $691m, commanding 64% of the six surveyed markets total. Over the forecast period, the value of this market will increase to $1.6bn, demonstrating a CAGR of 10.04%. Yervoy is currently the highest grossing melanoma drug in the US and the five major EU markets, generating 2011 sales of $360m. Few pipeline drugs are expected to actively compete with Yervoy over the forecast period, and Yervoy is forecast to generate sales of over $1bn by 2021. Quantify the performance of each of melanoma drug in the US and five major EU markets by sales and patient numbers. Gain insight into the key trends in individual melanoma markets across the US and five major EU markets. The report is accompanied by a PowerPoint presentation and Excel deliverable showing full melanoma forecasts for each country OVERVIEW


•Strategic scoping and focus•Datamonitor key findings

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs